Headline results from the cohort of non-hospitalised patients were presented from the Phase II trial (SG016) of SNG001 in SARS-CoV-2 infected patients as well as data from the combined analysis of the Hospital and Home Cohort. SNG001 treatment led to a threefold likelihood of recovering to ‘no limitation of activities’ in the markedly/severely breathless COVID-19 patients compared with those on placebo in the home and hospital setting; strengthening the efficacy signal and reinforcing the previo ....
30 Apr 2021
Synairgen - Home cohort Phase II (SG016) results
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Synairgen - Home cohort Phase II (SG016) results
Synairgen plc (SNG:LON) | 6.8 0 0.0% | Mkt Cap: 13.6m
- Published:
30 Apr 2021 -
Author:
Mark Brewer | Cavendish Research -
Pages:
9
Headline results from the cohort of non-hospitalised patients were presented from the Phase II trial (SG016) of SNG001 in SARS-CoV-2 infected patients as well as data from the combined analysis of the Hospital and Home Cohort. SNG001 treatment led to a threefold likelihood of recovering to ‘no limitation of activities’ in the markedly/severely breathless COVID-19 patients compared with those on placebo in the home and hospital setting; strengthening the efficacy signal and reinforcing the previo ....